Home > Arthritis News > 2006 Rituximab Receives FDA Approval for Treatment of Rheumatoid Arthritis The Food and Drug Administration (FDA) has now approved rituximab (Rituxan®) in combination with methotrexate for the treatment of rheumatoid arthritis (RA) in patients with moderate to severe rheumatoid arthritis who have had an inadequate response to one or more […]
Home > Arthritis News > 2006 Sleep Disturbance is Increased in Rheumatoid Arthritis Sleep quality has a profound affect on pain perception and mood, and poor sleep itself may affect immune function by increasing allostatic load. All of these effects may relate to the RA disease process. However, little investigation into sleep disturbance has been […]
Safety data obtained from randomized clinical trials designed to evaluate the efficacy of rheumatoid arthritis (RA) drugs can be misleading for several reasons. Often, the studies are short term (6 months or less), and are highly selective of the subjects included (usually subjects with very active disease and with few medical comorbidities). In addition, background DMARDs are usually restricted to methotrexate.
Tumor necrosis factor alpha (TNF-a) is a highly inflammatory cytokine with an important role in coordinating the inflammatory response seen in the axial skeleton of patients with ankylosing spondylitis (AS). Two biologic inhibitors of this cytokine, etanercept (Enbrel) and infliximab (Remicade), have been shown to be effective at reducing the subjective symptoms and reducing the systemic inflammatory response in AS in randomized clinical trials.
In addition to analgesic effects, animal studies have shown that inhibition of cyclooxygenase-2 (COX-2) is chemoprotective against colonic adenomas. In humans, the use of the COX-2 inhibitor celecoxib (Celebrex) has demonstrated anti-tumor activity in patients with familial adenomatous polyposis, a condition characterized by numerous colonic adenomas that often lead to frank colon cancer early in life.